31.97 -0.20 (-0.62%)
After hours: 4:11PM EDT
|Bid||32.03 x 900|
|Ask||32.16 x 800|
|Day's Range||31.47 - 32.49|
|52 Week Range||21.75 - 39.75|
|Beta (3Y Monthly)||1.57|
|PE Ratio (TTM)||18.40|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||0.40 (1.34%)|
|1y Target Est||44.00|
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Brooks Automation Inc (NASDAQ:BRKS), with a market cap of US$2.4b, are often out of the Read More...
Moody's Investors Service ("Moody's") affirmed Brooks Automation, Inc.'s (Brooks) B1 Corporate Family Rating ("CFR"), B1-PD Probability of Default Rating ("PDR"), the B1 ratings on the company's existing first lien term loan, and the SGL-1 Speculative Grade Liquidity ("SGL") rating.
Brooks Automation's (BRKS) acquisition of GENEWIZ Group for roughly $450 million is the company's largest in the life sciences space.
Inc. on Wednesday said it agreed to buy genomics service provider Genewiz Group for about $450 million in cash. Brooks, a Chelmsford, Mass., provider of automation and cryogenic solutions, said Genewiz expects to post revenue topping $140 million over the next 12 months, which corresponds to Brooks’ fiscal year. Brooks said Genewiz, based in South Plainfield, N.J., provides gene sequencing and synthesis services for more than 4,000 customers world-wide.
The purchase of New Jersey-based Genewiz Group is the company's "largest acquisition to date in life sciences."
CHELMSFORD, Mass., Sept. 26, 2018 /PRNewswire/ -- Brooks Automation, Inc. (BRKS) today announced that it has entered into a definitive agreement to acquire GENEWIZ Group, a leading global genomics service provider headquartered in South Plainfield, New Jersey. The total cash purchase price for the acquisition will be approximately $450 million, subject to working capital and other adjustments. The transaction is expected to close by the end of this calendar year upon satisfaction of customary closing conditions and regulatory approvals. GENEWIZ is a global leader in genomics services that enable research scientists to advance their discoveries within the pharmaceutical, academic, biotechnology, agriculture and other markets. The company provides gene sequencing and synthesis services for more than 4,000 institutional customers worldwide supported by their global network of laboratories spanning the United States, China, Japan, Germany and the United Kingdom. GENEWIZ, founded in 1999, is privately-held.
Brooks Automation Inc (NASDAQ:BRKS) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
CHELMSFORD, Mass., Sept. 5, 2018 /PRNewswire/ -- Brooks Automation, Inc. (BRKS), a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences, today announced that Michael Rosenblatt, M.D. has been elected to its Board of Directors. Dr. Rosenblatt is the chief medical officer of Flagship Pioneering, a unique life sciences innovation enterprise, and former chief medical officer of Merck. He previously served as the Dean of Tufts University School of Medicine and President of the Beth Israel Deaconess Medical Center.
Option's traders who opened bullish positions in Brooks Automation Inc. Tuesday morning tripled their money by noon. This was clearly a new position, as open interest in the strike was only 231 contracts before the activity appeared.
Robotics sector-related ETFs were among the best performers Tuesday after Swedish compressor and vacuum pump maker Atlas Copco (ATCO) made acquired Brooks Automation’s (NasdaqGS: BRKS) cryogenics business. ...
Swedish compressor and vacuum pump maker Atlas Copco is buying U.S.-based Brooks Automation's cryogenic business in a $675 million cash deal to expand its vacuum technology portfolio, the companies said late on Monday. The deal is Atlas Copco's biggest since the 2014 acquisition of Britain's Edwards Group, the base for its current Vacuum Technique business area. The acquisition also includes Brooks Automation's 50 percent share of Ulvac Cryogenics, Inc., a joint venture which had total sales of around $100 million in the fiscal year ending in June.
CHELMSFORD, Mass. , Aug. 27, 2018 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS) today announced that it has entered into a definitive agreement to sell its semiconductor cryogenics business to ...
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example. With anRead More...
Brooks Automation's (BRKS) third-quarter results benefit from robust performance across both the life sciences and the semiconductor solutions segments.
Brooks (BRKS) delivered earnings and revenue surprises of 1.96% and 2.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Chelmsford, Massachusetts-based company said it had profit of 32 cents. Earnings, adjusted for amortization costs and stock option expense, came to 52 cents per share. The supplier ...
CHELMSFORD, Mass. , Aug. 6, 2018 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS), a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Brooks Automation, Inc. (NASDAQ: BRKS ) will be discussing their earnings results in their Q3 Earnings Call to be held on August 6, 2018 at 5:00 PM Eastern ...
CHELMSFORD, Mass. , July 23, 2018 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS) will announce fiscal 2018 third quarter earnings, which ended on June 30, 2018 , on Monday, August 6, 2018 after ...
Stock Research Monitor: OLED, VECO, and BRKS LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on UMC sign up now at www.wallstequities.com/registration . WallStEquities.com presents ...